Vanderbilt-Ingram Cancer Center (VICC)

Nashville, Tennessee 37232

1 studies enrolling now · 7 studies all time

What they study most

Clear Cell Renal Cell Carcinoma, Graft Versus Host Disease, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma, Head and Neck Cancer, Lung Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Multiple Myeloma, NSCLC, Non-small Cell Lung Cancer, Non-squamous NSCLC

Studies at this site

• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation — Recruiting now
• A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma — Completed
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma — Stopped early
• Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin — Stopped early
• Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients — Stopped early
• Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE) — Stopped early
• A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology — Completed